Follow-up samples were processed within 24 h after collection. Analysis was carried out using the recently developed NGF methodology (Table S1), following the EuroFlow guidelines, as described elsewere20 (link),22 (link). Events from two eight-color tubes (per sample) were merged using the merge function of the INFINICYT™ v2.0 software (Cytognos S.L. Salamanca, Spain). A sample was considered positive when at least 20 aberrant plasma cells were detected. Hemodilution of bone marrow samples for NGF evaluation was assessed through the identification of a significant decrease in non-plasma cell populations: mast cells (CD117hi), erythroblasts (CD45/sideward-scatterlo) and B-cell precursors (CD19+/CD38hi/CD45lo). The complete analysis of NGF performance for the GEM2012 trial has already been published28 (link).
Free full text: Click here